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ABSTRACT 
Amongst its numerous functions, the liver is responsible for the synthesis and secretion of very 
low-density lipoprotein (VLDL). VLDL particles play the important role of facilitating the 
transport of lipids within the aqueous environment of the plasma; yet high plasma 
concentrations of these particles result in the pathogenesis of atherosclerosis, while low VLDL 
secretion from the liver results in hepatic steatosis. VLDL synthesis in the hepatocyte is 
completed in the Golgi apparatus, which serves as the final site of VLDL maturation prior to its 
secretion to the bloodstream. The mechanism by which VLDL’s targeted transport to the 
plasma membrane is facilitated has yet to be identified. Our lab has identified this entity. Our 
findings suggest that upon maturation, VLDL is directed to the plasma membrane through a 
novel trafficking vesicle, the Post-Golgi VLDL Transport Vesicle (PG-VTV). PG-VTVs containing 
[3H] radiolabeled VLDL were generated in a cell-free in vitro budding assay for study. First, the 
fusogenic capabilities of PG-VTVs were established. Vesicles were capable of fusing with the 
plasma membrane and delivering the VLDL cargo for secretion in a vectorial manner. The next 
goal of our study is to characterize key regulatory molecular entities necessary for PG-VTV 
biosynthesis. A detailed analysis was undertaken to determine the PG-VTV proteome via 
western blot and two-dimensional difference in gel electrophoresis. The identification of key 
molecular regulators will potentially offer therapeutic targets to control VLDL secretion to the 
bloodstream. 
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CHAPTER ONE: GENERAL INTRODUCTION 
For anything to have a significant impact it not only must be made correctly, but must 
be transported to its destination intact and functional. This is an absolute truth at the cellular 
level. 
Lipoproteins are particles consisting of proteins and lipids that facilitate the movement 
of lipids through the aqueous environment of the bloodstream. Lipoproteins are formed in 
order to protect the cell from the cytotoxic effect of high cytosolic concentrations of free Fatty 
Acids (FA) which lead to the disruption of the cell membrane and would result in cell death (1, 
2). VLDL is secreted into circulation where it is then digested into Intermediate Density 
Lipoprotein (IDL) and more importantly the atherogenic particle Low Density Lipoprotein (LDL). 
The vesicle-mediated secretory pathway, specifically the lipoprotein secretory pathway 
is an issue of high significance in the regulation of circulating lipoproteins implicated in 
coronary heart disease. Increased plasma concentrations of apolipoprotein B (apoB) containing 
lipoproteins, specifically LDL, have been shown to stimulate the pathogenesis of atherosclerosis 
(3, 4). Atherosclerosis currently poses an egregious predicament in the United States where 1 
out of every 6 deaths in 2008 was attributed to coronary heart disease and it is estimated that 
each minute an American dies due to a coronary event (5). The pathogenic atherogenic 
particles in circulation originate from hepatic secretion VLDL, which upon metabolism 
generates IDL and then LDL. VLDL biogenesis occurs in the liver where upon maturation is 
secreted into the circulatory system. 
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Absorption and metabolism of lipids is necessary for all forms of life, but due to the 
innate chemical properties of lipids which render them insoluble in the aqueous environment 
of blood a specialized organ is necessary for proper lipid metabolism. The liver is the organ that 
specializes in this process in mammalian species. It is here where potentially cytotoxic non-
esterified free fatty acids are converted to a more physiologically useful form of triacylglycerol 
(TAG) in the ER, which are then incorporated into TAG-rich VLDL molecules that are eventually 
secreted into the bloodstream. This is imperative not only due to the hydrophobic chemical 
properties of lipids which render them insoluble in the aqueous environment of the blood, but 
also in order to create a process which can be regulated depending on the fluctuating dietary 
needs of the organism. Therefore the liver must adapt to the FA influx and bind these 
hydrophobic lipids to lipoproteins that confer aqueous solubility and indirectly facilitate a 
process that allows for the regulation of lipid secretion into circulation. 
The sources of FA to the liver include the chylomicron remnants, dietary FA from the 
portal hepatic vein, and FA influx from adipocytes (1). The chylomicron is the lipoprotein 
particle synthesized and secreted from the intestine. Within the intestine, the nascent 
chylomicron is transported from the ER, its site of synthesis, to the Golgi membranes, its site of 
maturation, via a unique vesicle termed the Pre-Chylomicron Transport Vesicle (PCTV) (1, 6). 
The PCTV signifies the importance of transport vesicles in intracellular lipoprotein trafficking 
and alludes to the mechanism that mediates VLDL transport within the hepatocyte. 
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VLDL Biogeneration 
VLDL consists of a core of neutral triacylglycerol (TAG), cholesterol esters, specific 
apolipoproteins, surrounded by a monolayer of amphipathic phospholipids and unesterified 
cholesterol (7, 8). Newly synthesized VLDL particles range in size between 30-100 nm in 
diameter (7, 9). The main apolipoprotein associated with VLDL is apoB, which serves as the 
structural backbone for VLDL, IDL, and LDL (3, 10). Each VLDL particle contains one and only one 
apoB molecule, and thus understanding this protein is of great importance. 
There exist two major forms of apoB, the fully translated apoB100 and apoB48. ApoB is 
a large hydrophobic glycoprotein with the fully translated apoB100 sequence consisting of 4536 
amino acids and molecular weight of 520 kDa (11-13). The apoB48 form corresponds to the 
peptide of 48% of the full-length protein of approximately 250 kDa. This occurs due to an 
apobec-1 mediated mRNA editing of the apoB transcript which causes a C-to-U deamination of 
a cytidine at nucleotide 6666 which normally would encode a glutamine codon (CAA), resulting 
in a premature translational stop codon (UAA) (14, 15). In humans, apoB100 is associated with 
VLDL produced in the liver, while apoB48 is associated with chylomicrons produced in the 
intestine (1). In rodents however, both apoB100 and apoB48 are synthesized and secreted by 
the liver (15). ApoB100 has a pentapartite structure (NH2−α1−β1−α2−β2−α3−COOH) consisting of 
three alpha helix domains that bind lipid reversibly and two beta sheet domains that 
irreversibly bind lipids (12). This association allows the peptide to be exposed on the surface 
while interacting with lipids and thus allows its associated lipids to traverse the aqueous 
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environment of the bloodstream. The synthesis and regulation of this protein are unique and 
allude to its significant role in the hepatocyte. 
 
 
Figure 1 – VLDL Molecule 
Cross-section of a Very Low Density Lipoprotein particle. 
 
 
Amongst the liver’s many vital functions, the synthesis and secretion of VLDL is a 
complex pathway of utmost importance. The first step of VLDL biogeneration begins at the 
surface of the hepatic Endoplasmic Reticulum (ER) with the synthesis of apoB. Nascent apoB is 
targeted into the ER by its N-terminal signal-peptide sequence of 27-amino acids. The 
translocation of nascent apoB occurs through translocons occurs simultaneously with 
translation, however this translocation is not continuous (16, 17).  
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The level of apoB100 in the liver is regulated not by its synthesis, but by the level of 
degradation (18). Nascent apoB100 that fails to be lipidated in the lumen of the ER is directed 
to the ubiquitin-proteasome pathway for degradation in a process called ER Associated 
Degradation (ERAD). While most protein that are directed to the ERAD are degraded due to 
improper translation ultimately leading to misfolding, apoB100 is unique in that when it is 
poorly lipidated, it is sent for degradation, thus regulating its synthesis based on the availability 
of core lipids (18). This has been shown through the use of MTP inhibitors which reveal that 
upon inhibition of MTP function, apoB is degraded and if proteasome inhibitors are also 
introduced there leads to an accumulation of secretion-incompetant apoB100 within the 
hepatocytes (19). The mechanism of ERAD degradation involves the partial translation and 
translocation of the nascent apoB100, then interaction with the cytosolic chaperone Hsp70, 
followed by polyubiquitinylation and association with Hsp90 that directs the peptide to the 
proteasome (20-22). This process also involves the association of P58IPK, Hsp110, p97, and BiP, 
which regulate the secretion of apoB through the ERAD (23-26). 
VLDL assembly occurs via a two-step process (27). This newly synthesized apoB100 
molecule is first partially lipidated on its N-terminus through the action of microsomal 
triglyceride transfer protein (MTP). MTP is a lipid transfer enzyme consisting of a dimer of two 
polypeptides, a 55 kDa ‘P’ subunit which is an ER resident enzyme protein disulfide isomerase 
(PDI), and a 97 kDa ‘M’ subunit which is the subunit responsible for catalyzing the transfer of 
phospholipids, cholesterol esters, and TAG to apoB100 (28, 29). MTP has three functional 
domains, an apoB binding domain, a lipid transfer domain, and a membrane associating domain 
 6 
(28). The second step of VLDL formation involves the conjugation of this poorly-lipidated VLDL 
particle with the bulk of its lipid (30). 
 
VLDL Trafficking 
Upon synthesis, this premature VLDL particle must be transported from the ER to the 
Golgi apparatus for maturation (31, 32). The VLDL Transport Vesicle (VTV) has been identified 
as the vesicle that mediates this transport step (33). The VTV is unique to other ER-to-Golgi 
transport vesicles characterized presently, such as the Protein Transport Vesicles (PTVs) 
responsible for transporting protein to the Golgi (7, 33). The VTV is unique in both its proteome, 
morphology, tethering proteins and cargo (33, 34).  
The formation of the VTV from the ER membranes is dependent upon coat-complex II 
(COPII) proteins. These are a group of cytosolic proteins that facilitate the formation of vesicles 
and mediate cargo-selection for these vesicles. The COPII complex consists of the proteins Sar1, 
Sec23-Sec24, and Sec13-Sec31 (35-38). The formation of the COPII coat begins with the guanine 
nucleotide exchange factor Sec12, which mediates the exchange of the GDP form of Sar1 to 
Sar1-GTP (39). Sar1-GTP then recruits the heterodimer Sec23-Sec24, which is followed by the 
recruitment of the Sec13-Sec31 heterotetramer. This formation triggers membrane 
deformation and the budding of the vesicle from the ER membrane (7, 38). It is important to 
note that there are two mammalian isoforms of Sar1. Sar1a is responsible for the ER-to-Golgi 
transport of nascent proteins, while Sar1b is the isoform that mediates the transport of 
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lipoproteins (40-42). To accommodate the larger cargo, the COPII cage is expanded by complex 
with the cideB protein (43). 
The soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
proteins are the tethering proteins responsible for the targeted delivery of vesicles to their 
destination and allow for the formation of the vesicular fusion complex (44, 45). The SNARE 
complex required for fusion of VTV with Golgi membranes consists of the vesicular-SNARE (v-
SNARE) Sec22b on the VTV, and the target-SNAREs (t-SNARE) syntaxin5, rBet1, and GOS28 on 
the Golgi membranes (46). 
Upon arrival within the Golgi lumen, several important modifications occur to VLDL that 
are prerequisites to its secretion from the hepatocyte including additional phosphorylation and 
glycosylation of its structural apoB100 protein (47-50). It is within the Golgi lumen that VLDL 
matures further by the incorporation of apolipoproteinAI (apoAI) and apolipoproteinE (apoE) 
(49).  
Mature VLDL must then be delivered to the plasma membrane (PM) for secretion from 
the hepatocyte. Its large size of approximately 80-100nm in diameter suggests that it requires a 
specific intracellular compartment to facilitate this trafficking step (33). The presence of lipases 
and proteases in the cytosol also strongly suggest the need for a sealed compartment to 
protect its cargo from digestion. Moreover the mature VLDL molecule must be specifically 
directed towards the plasma membrane for secretion. 
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Figure 2 – VLDL Transport Pathway 
Overview of the intracellular VLDL trafficking pathway. VLDL is synthesized in the ER lumen and 
transported via the VTV to the cis-Golgi for maturation. Upon maturation it is transported to 
the plasma membrane for secretion from the hepatocyte via the newly isolated PG-VTV vesicle. 
 
 
The transport of mature VLDL to the plasma membrane is a prerequisite for its eventual 
secretion from the hepatocyte. This trafficking step is a directed means and thus alludes to the 
fact that a vesicle must facilitate this transport. The fact that this cargo is unique in size and 
biochemical composition to other molecules suggests that a specific vesicle must be responsible 
for the transport step. Moreover this specific vesicle must have the capability to enclose its 
mature VLDL cargo, traverse the cytosol and specifically deliver its cargo to the plasma 
membrane for secretion.  
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Vesicle budding and fusion is of utmost importance for transport of specific cargo 
between subcellular organelles and eventual secretion out of cells (51). Regulation of vesicular 
transport at the level of the trans-Golgi network (TGN) is physiologically vital to the generation 
of basolateral and apical membranes in polarized cells, and for sorting cargo for transport from 
the TGN (52-55). The significance of Golgi regulation has been shown with studies on protein 
containing vesicles where Golgi lipids such as phosphoinositides have been shown to play a role 
in the recruitment of trafficking components such as clatherin coats (56, 57), while 
glycosphingolipids and cholesterol levels have been hypothesized to play a role in segregating 
components into lipid rafts (58). Furthermore these studies have indicated the significance of 
the continuous membrane flow characteristic to the Golgi as being important for directing 
cargo for secretion (59), and have identified that these Golgi derived vesicles are initially 
formed by a tubule like extension of trans-Golgi network membranes and their subsequent 
membrane fission resulting in vesicles (60, 61). 
Although much is known on clathrin- (mediate plasma membrane to TGN vesicular 
transport of endosomes), COPI- (retrograde vesicle transport from Golgi to the ER and more 
recently retrograde transport from endosomes to TGN), and COPII- vesicles (anterograde ER to 
Golgi transport) (62, 63), the synthesis, protein composition, and tethering SNARE protein 
complex responsible for directional trafficking and targeting of Golgi-to-Plasma membrane 
vesicles is not yet fully characterized.  
It is for these reasons that the hypothesis is that mature VLDL exits the Golgi in a unique 
specialized vesicle which is unique in morphology, size, proteomic composition, and that this 
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vesicle is functional in its ability to deliver its VLDL cargo to the plasma membrane for secretion 
from the hepatocyte. The mechanism by which this investigation will be carried out involves 
first, generating Golgi-derived lipoprotein vesicles, followed by conducting morphological and 
biochemical studies on these vesicles. Upon confirmation that these vesicles are indeed unique 
and are capable of enclosing mature VLDL cargo, a proteomic analysis will be conducted to 
analyze these vesicles and compare them to previously identified hepatic lipoprotein vesicles, 
specifically the VTV. The intent of this study is to elucidate the requirements for Golgi-derived 
VLDL transport vesicle biogeneration and to identify its proteome. This study indicates that the 
PG-VTV is a novel Golgi to plasma membrane vesicle unique in size, buoyant density, cargo, and 
proteome and is responsible for the secretion of fully matured VLDL from hepatocytes. The 
significance of these studies are vast, as this will provide a basic tool for cardiovascular, and 
more specifically, lipoprotein research. 
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CHAPTER TWO: EXPERIMENTAL PROCEDURES 
Materials 
[3H]OA (oleic acid; 45.5 Ci/mM) was acquired from Perkin Elmer Life Sciences (Boston, MA). 
Protease inhibitor cocktail tablets were acquired from Roche Applied Science (Indianapolis, IN). 
Gel electrophoresis and immunoblotting reagents were acquired from Bio-Rad (Hercules, CA). 
Enhanced chemiluminescence (ECL) reagents were acquired from GE Healthcare Life Sciences 
(Pittsburgh, PA). Other reagents used were of analytical grade and purchased from local 
companies. Sprague-Dawley rats (150-200 g) were acquired from Harlan (Indianapolis, IN). All 
procedures involving animals were conducted according to the guidelines of the University of 
Central Florida’s Institutional Animal Care and Use Committee (IACUC) and strictly following the 
IACUC-approved protocol. 
 
Antibodies 
Rabbit polyclonal anti-apolipoproteinB (apoB) antibodies were generated commercially (Protein 
Tech Group, Chicago, IL) using a synthetic peptide corresponding to amino acids 2055-2067 of 
rat apoB. Goat polyclonal anti-apoAIV, anti-apoE, anti-calnexin, anti-GOS28, anti-syntaxin 
antibodies; rabbit polyclonal anti-L-FABP antibody; and mouse monoclonal anti-Sec22b, anti-
TGN38 antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Rabbit 
polyclonal anti-Sar1 antibodies were generated commercially and have been described 
previously. Rabbit polyclonal antibodies against rat VAMP7 (vesicle-associated membrane 
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protein 7; amino acids 105-123) have been described previously. Rabbit polyclonal antibodies 
to apoAI; and Mouse monoclonal antibodies to alpha 1 Sodium Potassium ATPase were 
purchased from Abcam (Cambridge, MA). Goat anti-Mouse IgG, Goat anti-Rabbit IgG, and 
Rabbit anti-Goat IgG conjugated with horseradish peroxidase (HRP) were purchased from Sigma 
Chemical Co. (St. Louis, MO). 
 
Isolation and Purification of Subcellular Organelle Samples 
Preparation of Radiolabelled Hepatic ER, cis-, and trans-Golgi 
Perfusion of rat liver with calcium-free Kreb’s Buffer [119 mM NaCl, 4.7 mM KCl, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3; pH 7.4] followed by collagenase perfusion [11,000 
units per liver (51 mg Type II collagenase per 150ml Kreb’s buffer)] was performed. The liver 
was immediately harvested and primary hepatocytes were immediately isolated by chopping 
the liver and pushing the sample through a 100-micron sieve. Cells were washed in Kreb’s 
buffer twice, then incubated in Buffer B [136 mM NaCl, 11.6 mM KH2PO4, 7.5 mM KCl, 0.5 mM 
dithiothreitol, 8mM Na2HPO4; pH 7.2] with BSA complexed to [
3H]OA (150 μCi) for 35 minutes 
at 37°C. Cells were then washed twice with 2% BSA in PBS to remove excess [3H]OA. Cells were 
then homogenized in [0.25 M Sucrose in 10 mM HEPES pH 7.2, 50mM EDTA, and protease 
inhibitor] using a Parr Bomb at 1,000 psi for 40 minutes. A post-nuclear supernatant (PNS) was 
prepared, then pelleted and the resulting pellet was adjusted to 1.2 M sucrose in 10 mM 
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HEPES. ER, cis- and trans-Golgi fractions were separated using a sucrose step gradient (1.15 M, 
0.86 M, 0.25 M). 
Preparation of Hepatic Cytosol 
Rat primary hepatocytes were washed in Kreb’s buffer following isolation from freshly 
harvested rat liver perfused with collagenase. Cells were washed with cytosol buffer [25 mM 
Hepes, 125 mM KCl, 2.5 mM MgCl2, 0.5 mM DTT and protease inhibitors; pH 7.2], and 
homogenized with a Parr bomb at 1,000 psi for 40 minutes, followed by ultracentrifugation at 
165,000 × g for 95 minutes (Beckman Rotor Type 70 Ti). To remove endogenous ATP and GTP, 
supernatant was dialyzed against ice-cold cytosol buffer overnight at 4°C.  Cytosol was 
concentrated using a centricon filter (Amicon, Beverly, MA) and ultra filtration membrane 
(Millipore, Billerica, MA) with a cut- off of 10 kDa. 
Preparation of Hepatic Plasma Membrane 
Rat liver was harvested following perfusion with Kreb’s buffer, chopped, washed with 0.25 M 
Sucrose with protease inhibitor and EDTA, then centrifuged at 600 × g for 10 minutes. The Post 
Nuclear Supernatant (PNS) was collected, homogenized with 0.25 M sucrose and centrifuged at 
38,400 × g for 10 minutes (Fiberlite F21S-8x50y rotor). The pellet was homogenized with 57% 
(w/v) sucrose until 47% sucrose (w/v) based on reading in refractometer and laid under a 
discontinuous sucrose step gradient of 37.2% (w/v) sucrose and 0.25 M sucrose, then 
ultracentrifuged at 106,600 × g (Beckman SW 32 Ti) for 16 hours at 4°C. The fraction was 
collected at the interface of the 0.25 M sucrose and 37.2% (w/v) fractions. Sample was then 
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adjusted to 14.6% sucrose and the PM was purified from Golgi membranes by being overlaid on 
a discontinuous sucrose gradient (23.7%, 30.8%, 38.1%), ultracentrifuged at 124,800 × g 
(Beckman Rotor SW 41 Ti) for 2 hours at 4°C. PM was collected at the 38.1% (w/v) and 30.8% 
(w/v) interface by aspiration. 
Determination of Protein Concentration and Assessment of Sample Purity 
The protein concentration of the samples was determined using the Bradford method. Samples 
were assessed for purity by testing for the presence of marker protein via immunoblotting. 
 
In vitro Golgi-derived Vesicle Budding Assay 
PG-VTVs were generated in a cell-free in vitro vesicular budding assay. Rat hepatic Golgi 
membranes (200 μg of protein) were incubated with hepatic cytosol (500 μg of protein), an 
ATP-generating system [1 mM ATP, 5 mM phospho-creatine and 5 units of creatine 
phosphokinase], 1 mM GTP, 1mM E600, 5 mM Mg2+, 5mM DTT and 5mM Ca2+, and the reaction 
mixture volume was adjusted to 500 μl by addition of transport buffer [30 mM Hepes, 250 mM 
sucrose, 2.5 mM MgOAc, 30 mM KCl; pH 7.2] for 30min at 37°C in the absence of Plasma 
Membrane acceptor. The reaction was terminated by placing the tubes on ice and diluted to 0.1 
M with cold 10 mM HEPES. The reaction mixture was then overlaid on top of a continuous 
sucrose gradient (0.1 M to 0.86 M sucrose in 10 mM HEPES), ultracentrifuged at 115,000 × g 
(Beckman Rotor SW 41 Ti) for 2 hours at 4°C. Fractions of 500 μl were collected by aspiration 
and dpm of fractions was determined using a liquid scintillation counter. 
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In vitro PG-VTV – Plasma Membrane Fusion Assay 
To demonstrate fusion, PG-VTV (150 μg of protein) was incubated with rat hepatic PM (150 μg 
of protein), cytosol (500 μg of protein), an ATP regenerating system, Mg2+, Ca2+, DTT, E600, 
Transport Buffer and incubated at 37°C for 35 minutes. Reaction was stopped by placing tubes 
on ice and reaction mixture was adjusted to 14.6% (w/v) with 23.7% (w/v) cold sucrose in 10 
mM HEPES and overlaid upon a discontinuous sucrose gradient (23.7%, 30.8%, 38.1% sucrose in 
10 mM HEPES) and ultracentrifuged at 124,800 × g (Beckman Rotor SW 41 Ti) for 2 hours at 4°C. 
500 μl Fractions were collected at intermediate of 38.1% and 30.8% (w/v) interface by 
aspiration and dpm was determined using a liquid scintillation counter. 
 
Measurement of Radioactivity 
Radioactivity associated with [3H]TAG was quantitated in terms of disintegrations per minute 
(dpm) using the single-isotope mode on a liquid scintillation analyzer (TriCarb, Model 2910, 
Perkin Elmer Life and Analytical Sciences, Shelton, CT). 
 
Electron Microscopy 
The negative staining technique of electron microscopy was utilized to examine the 
morphology of PG-VTVs. A formvar-carbon coated nickel grid was placed on a drop of 
concentrated PG-VTV fraction for 2–3 minutes, rinsed with PBS and water. The grid was then 
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stained with 0.5% aqueous uranyl acetate, air-dried, and examined at 10,000x magnification 
using an FEI Morgagni 268(D) transmission electron microscope (FEI, Hillsboro, Oregon). 
 
Gel Electrophoresis and Immunoblot Analysis 
Samples (40 μg of protein) were solubilized in Laemmli’s Buffer (1X final concentration) and 
resolved via SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) (12% gel for single percentage 
gels, 4-20% gel for gradient gels) at 20 mAmp until tracking dye reached the end of the gel. 
Proteins were then transblotted onto nitrocellulose membranes (Bio-Rad) at 50 mAmp 
overnight at 4°C. The membrane was then blocked with 10% (w/v) non-fat dried skimmed milk 
in PBS-T, incubated with specific primary and then the appropriate secondary antibodies 
conjugated with HRP. Protein was detected using ECL reagents and exposing to Film (MIDSCI, 
St. Louis, MO). 
 
Two-Dimensional Gel Electrophoresis (2D-Gel) 
Sample (150 μg of protein) was incubated in Rehydration Sample Buffer [7 M urea, 2 M 
thiourea, 2% (w/v) CHAPS, 0.5% (v/v) carrier ampholyte (pharmalyte pH 3-10), 0.002% 
Bromophenol blue, 20 mM DTT] and incubated at 37°C for 1 hour. 
Sample was immediately loaded via anodic cup loading onto 11 cm IPG strip (pH 3-10 linear 
gradient) (GE Healthcare) that had been rehydrated at room temperature overnight in 
Rehydration Buffer [7 M urea, 2 M thiourea, 2% (w/v) CHAPS, 0.5% (v/v) carrier ampholyte 
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(pharmalyte pH 3-10), 0.002% bromophenol blue, 1.2% DeStreak Reagent]. The IPGphor III 
system was used to subject samples to isoelectric focusing for 52,000 Volt hours at 20°C at 50 
μAmp/strip.  
The IPG strip was then equilibrated for SDS-PAGE immediately following IEF by incubating for 
15 minutes in SDS Equilibration Buffer I (Reducing Buffer) [6 M urea, 75 mM Tris-HCl (pH 8.8), 
29.3% (v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue, 1% DTT] at room 
temperature, then subsequently incubated for 15 minutes in SDS Equilibration Buffer II 
(Alkylation Buffer) [6 M urea, 75 mM Tris-HCl (pH 8.8), 29.3% (v/v) glycerol, 2% (w/v) SDS, 
0.002% (w/v) bromophenol blue, 2.5% iodoacetamide] at room temperature. The IPG strip was 
then loaded onto a 10% SDS-PAGE gel, sealed with 0.75% agarose, and resolved at 15 mAmp for 
1 hour, then at 20 mAmp until the dye reached the end of the gel. 
The gel was immediately silver stained and scanned. 
 
Two-Dimensional Difference In Gel Electrophoresis (2D-DIGE) 
Sample Preparation and Minimal Fluorescent Labeling 
Samples (50 μg of protein) were incubated with Lysis Buffer [7 M urea, 2 M thiourea, 30 mM 
Tris, 4% (w/v) CHAPS; pH 8.5] for 15 minutes on ice. No primary amines, DTT, or carrier 
ampholytes were in the lysis buffer as these could react with the N-hydroxysuccinimide ester 
group of the CyDye resulting in reduced concentration of fluorophore available for protein 
labeling. Samples were separately labeled with 400 pmol Cy3 or Cy5 fluorescent dye, vortexed, 
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briefly centrifuged, and incubated on ice for 30 minutes in the dark. The labeling reaction was 
stopped and unreacted dye was quenched by the addition of 10 mM L-lysine to each sample 
and incubation on ice for 10 minutes in the dark. Both of the labeled samples were then 
combined and incubated with 2D DIGE Sample Buffer [7 M urea, 2 M thiourea, 2% (w/v) CHAPS, 
2% (v/v) carrier ampholyte (pharmalyte pH 3-10), 0.002% Bromophenol blue, 15 mM DTT] and 
incubated on ice for 15 minutes in the dark. 
Isoelectric Focusing (IEF) and SDS-PAGE 
Samples were immediately loaded via anodic cup loading onto 11 cm IPG strip (pH 3-10 linear 
gradient) (GE Healthcare) that had been rehydrated at room temperature overnight in 
Rehydration Buffer [7 M urea, 2 M thiourea, 2% (w/v) CHAPS, 0.5% (v/v) carrier ampholyte 
(pharmalyte pH 3-10), 0.002% bromophenol blue, 1.2% DeStreak Reagent]. The IPGphor III 
system was used to subject samples to isoelectric focusing for 52,000 Volt hours at 20°C at 50 
μAmp/strip.  
The IPG strip was then equilibrated for SDS-PAGE immediately following IEF by incubating for 
15 minutes in SDS Equilibration Buffer I (Reducing Buffer) [6 M urea, 75 mM Tris-HCl (pH 8.8), 
29.3% (v/v) glycerol, 2% (w/v) SDS, 0.002% (w/v) bromophenol blue, 1% DTT] at room 
temperature, then subsequently incubated for 15 minutes in SDS Equilibration Buffer II 
(Alkylation Buffer) [6 M urea, 75 mM Tris-HCl (pH 8.8), 29.3% (v/v) glycerol, 2% (w/v) SDS, 
0.002% (w/v) bromophenol blue, 2.5% iodoacetamide] at room temperature. The IPG strip was 
then loaded onto a 10% SDS-PAGE gel, sealed with 0.75% agarose, and resolved at 15 mAmp for 
1 hour, then at 20 mAmp until the dye reached the end of the gel.  
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Image Scan and Data Analysis 
The gel was immediately scanned using a Typhoon TRIO scanner (GE Healthcare) at the 
manufacturer specified excitation and emission wavelengths at 100 μm resolution. Scanned 
images were generated and analyzed using ImageQuant software (version 5.2, GE Healthcare). 
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CHAPTER THREE: PG-VTV BIOGENERATION 
In order to study the downstream steps of VLDL trafficking within the hepatocyte, a cell 
free in vitro budding assay was utilized to study the formation of the VLDL containing vesicles 
from Golgi membranes. Golgi membranes, cytosol, ER, and PM subcellular organelles were 
isolated from hepatocytes for use in this cell free assay. The aim was to establish that VLDL exits 
the Golgi apparatus in a process mediated by a specialized vesicle; to establish this vesicle’s 
functionality and specificity in targeting the plasma membrane for delivery of its VLDL cargo; 
and to identify the requirements for its biogenesis. 
 
Assessment of Hepatic Subcellular Organelle Purity 
As our means of studying VLDL vesicles is under cell free in vitro assays, organelle purity 
is of great importance. In order to proceed with confidence, the purity of isolated organelle 
samples were initially assessed by the presence of their specific marker proteins. Marker 
proteins were utilized in order to verify isolation of organelles was indeed successful and that 
no contamination was present. Specific marker proteins, or proteins unique to that organelle 
were tested for by western blot analysis. Table 1 shows the organelle marker proteins used for 
assessing purity. 
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Table 1 – Hepatic Subcellular Organelle Marker Proteins 
Organelle Marker Protein Protein Molecular Weight 
Endoplasmic Reticulum Calnexin 90 kDa 
Golgi Apparatus GOS28 
TGN 38 
28 kDa 
38 kDa 
Plasma Membrane Na-K ATPase 112 kDa 
 
 
 
Figure 3 – Organelle Purity 
Western blot data for hepatic cytosol, Golgi, and ER samples (left); and Golgi, Plasma 
Membrane, and Cytosol samples (right). Samples (40 μg of protein) were resolved on a 12% 
SDS-PAGE gel. 
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As shown in Figure 3, isolated Golgi membranes contained GOS28 and TGN38, marker 
proteins for the cis-Golgi and trans-Golgi, respectively. The Golgi membranes isolated were free 
of ER contamination as shown by the absence of Calnexin, a resident ER protein. Isolated ER 
membranes contained Calnexin and sample purity was assessed by the absence of GOS28 and 
TGN38. As expected, PM fractions contained the Na-K ATPase protein. Purity of the cytosol 
sample was assessed by the absence of organelle specific marker proteins Calnexin, GOS28, 
TGN38, and Na-K ATPase while containing the cytosolic protein L-FABP. 
To further demonstrate that each organelle sample was unique in proteome, two 
dimensional electrophoresis gel (2D-Gel) analysis was conducted. The 2D-gel spot pattern for 
each organelle was unique as shown in Figure 4. 
 
 
Figure 4 – Organelle 2D-Gels 
Hepatic cytosol, ER, and Golgi membranes were resolved on 2D-Gel (pH 3-10 first dimension, 
10% SDS-PAGE second dimension). Cytosol and ER samples (150 μg protein) were silver stained 
immediately after the second dimension. Golgi sample (50 μg protein) was labeled with Cy3 and 
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scanned immediately following the second dimension. Gels were analyzed for general shape 
and spot pattern. 
 
 
Together, western blotting data and 2D-gel data indicate that the isolated hepatic 
subcellular organelle samples were of sufficient purity to use in subsequent experiments. 
 
Cell-Free in vitro Golgi Budding Assay and Assessment of VLDL 
Prior to isolating the organelle samples, VLDL within hepatocytes were radiolabeled by 
incubating the hepatocytes with [3H]Oleic Acid, which would then be incorporated into [3H]TAG 
and conjugated with VLDL. This allowed the detection of VLDL in downstream assays by 
assessment of radioactivity. Golgi membranes containing radiolabeled mature VLDL were 
incubated at 37°C in the presence of cytosol and an ATP regenerating system under conditions 
that promoted vesicular generation, or budding, from the Golgi membranes. The reaction was 
terminated and immediately resolved on a continuous sucrose gradient (0.1 M to 0.86 M). 
Under these conditions it is expected that vesicles containing VLDL would float to the top due 
to their light buoyant density as a result of their high TAG content, while the remaining Golgi 
membranes would pellet. This technique is illustrated in Figure 5. 
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Figure 5 – Budding Assay for PG-VTV Biogeneration 
Overview of the cell-free in vitro budding assay utilized to generate PG-VTVs. Rat primary 
hepatocytes were isolated from freshly harvested rat liver and incubated with radiolabelled 
[3H]OA. Organelles containing radiolabeled VLDL were isolated and incubated under conditions 
to promote vesicle formation. Vesicles were isolated on a continuous sucrose gradient. 
 
 
This gradient was then separated into sequential fractions and assessment of 
radioactivity by dpm count of each fraction was conducted. The presence of VLDL was indicated 
by a high dpm count indicating the presence of [3H]TAG. As shown in figure 6, the lightest 
density fractions contained a peak in radioactivity indicating the presence of VLDL containing 
vesicles of Golgi origin.  
 
 25 
 
Figure 6 – [
3
H]TAG Radiolabelled VLDL Along Continuous Sucrose Gradient 
Total dpm count along the continuous sucrose gradient. Green line corresponds to the 
increasing sucrose gradient. Orange line corresponds to the negative control (no cytosol), while 
the blue line is the actual experiment. Data reveals the high concentration of dpm in the first 
three fractions. 
 
 
Vesicle Purity from Organelle Contamination 
Isolated PG-VTVs did not contain organelle marker proteins, suggesting they were 
specifically formed VLDL transport compartments and not merely fragments of broken 
organelle membranes. As shown in Figure 7 PG-VTVs did not contain the Golgi marker protein 
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GOS28, nor the SNARE protein Sec22B, which is present on VTVs and localizes to ER 
membranes. 
 
 
Figure 7 – PG-VTV Purity From Organelle Contamination 
Western blot analysis of Cytosol, Golgi, PG-VTV, and ER. Samples (40 μg protein) were resolved 
on a 4-20% gradient SDS-PAGE gel. 
 
 
Morphology of PG-VTV 
The negative staining technique of electron microscopy was utilized to examine the 
morphology of the PG-VTVs. Fractions 1-3, which contained peak dpm counts, were 
concentrated and observed. As shown in the figure 8, these light-density fractions contained 
several vesicles. Moreover, these vesicles were approximately 300nm in diameter, an adequate 
size to harbor a VLDL sized particle (80-100nm diameter). 
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Figure 8 – Morphology of PG-VTV 
PG-VTV vesicles were concentrated from fractions 1-3 of continuous sucrose gradient and 
analyzed utilizing negative staining technique of electron microscopy. 
 
 
Requirements for PG-VTV Budding 
The requirements for PG-VTV biogenesis from Golgi membranes were identified. The 
post-Golgi budding assay was repeated under several conditions. To assess the requirement of 
physiological temperature, the assay was repeated at 4°C. PG-VTV budding requires energy in 
the form of ATP as vesicular formation was significantly abrogated when the ATP regenerating 
system was replaced with apyrase, an enzyme which digests ATP. Cytosolic proteins are 
necessary for proper PG-VTV formation, as no budding occurs when cytosol was replaced with 
cytosolic buffer. As figure 9 shows, the formation of VLDL containing vesicles requires ATP, 
 28 
cytosolic protein, and incubation at 37°C. When these conditions are not met, budding was 
significantly abrogated. 
 
 
Figure 9 – PG-VTV Budding Requirements 
Cell-free in vitro budding assay was performed under conditions of apyrase replacing ATP, 4°C, 
and no hepatic cytosol. Each condition significantly abrogated dpm signal. 
 
Fusion with Plasma Membrane 
The functionality of PG-VTVs was assessed by their fusogenic properties, specifically 
fusion with the plasma membrane and delivery of their VLDL cargo to the plasma membrane. 
This was characterized through a cell free in vitro fusion assay with isolated hepatic plasma 
membrane sample. A characteristic of vesicle-mediated trafficking is the ability of the specific 
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vesicle to deliver its cargo to its destination through a directed mechanism. This fusion assay is 
illustrated in figure 10.  
PG-VTVs incubated with hepatic plasma membrane were successful in transferring their 
VLDL cargo to plasma membrane destination. Importantly this trafficking step required access 
to the cytosolic side of the plasma membrane. Isolation of plasma membrane results in vesicle 
like compartments oriented identical to the intact hepatocytes. A series of freeze/thaw cycles 
in liquid nitrogen are required to flip the plasma membrane vesicles and expose their cytosolic 
side. Figure 11 illustrates the steps required to expose cytosolic side of plasma membrane to 
the vesicles for fusion. Upon exposure of the cytosolic side, the PG-VTVs are able to bind with 
the plasma membrane and deliver their VLDL cargo to these PM compartments. 
 
 
Figure 10 – Fusion Assay 
PG-VTVs were incubated with hepatic cytosol and plasma membrane. Reaction was then 
resolved on a discontinuous sucrose gradient and PM interface was isolated at its expected 
density. Fusion of vesicles with plasma membrane was signified by VLDL becoming isodense 
with the plasma membrane signifying a transfer of dpm to the plasma membrane interface. 
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Figure 11 – Plasma Membrane Orientation 
Shown is a model illustrating the necessity to flip plasma membrane in order to expose its 
cytosolic side to vesicles. Upon isolation of plasma membrane from intact hepatocytes, vesicle-
like structures form with the same orientation as intact hepatocyte. To expose cytosolic side, 
plasma membrane sample was freeze/thawed in liquid nitrogen and 20°C water bath for 5 
cycles. 
 
 
Importantly, this transport was unidirectional; vesicles were able to fuse with the 
plasma membrane but not with Golgi membranes indicating their specificity in transporting 
VLDL in a vectorial manner along the secretory pathway. As shown in figure 12, PG-VTVs were 
capable of transferring VLDL, indicated by a transfer of dpm, to the plasma membrane under 
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conditions of 37°C, access to properly oriented plasma membrane, and presence of cytosolic 
protein. 
 
 
Figure 12 – Transfer of [3H]TAG dpm 
Total dpm count of PG-VTV fusion under conditions of no cytosol, 4°C, inverted plasma 
membrane, and incubation with Golgi membranes. 
 
 
Taken together, this data strongly suggests the isolation of a specialized VLDL transport 
vesicle. This vesicle facilitates VLDL exit from the trans-Golgi face, directed transport to the 
plasma membrane, and delivery of cargo for secretion from the hepatocyte. The biogenesis of 
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the PG-VTV requires the presence of cytosol, energy in the form of ATP, and incubation at 37°C. 
The fusion and delivery of the cargo requires the presence of cytosol, incubation at 37°C, access 
to the cytosolic side of the plasma membrane, and importantly is a unidirectional means of 
transporting mature VLDL from the Golgi to the PM. 
This vesicle is unique in its proteome and is fully functional and can not only specifically 
select its cargo for secretion from the hepatocyte, but transports this cargo in a unidirectional 
manner further attesting to its specificity and novelty. 
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CHAPTER FOUR: PROTEOMIC ANALYSIS 
The next aim of the study was to conduct a proteomic profile of the newly isolated PG-
VTV. Fully describing the PG-VTV proteome will create a new research tool that may prove to 
be an aid in ultimately elucidating the lipoprotein secretory pathway. This tool may potentially 
facilitate the identification of key regulatory proteins in the intracellular trafficking of matured 
VLDL and potentially identify key molecular targets for cardiovascular drug therapy. Moreover, 
a proteomic analysis will aid in understanding the mechanism PG-VTV function, necessary as its 
function is a vital downstream step in the secretion of VLDL from the hepatocyte.  
 
Proteomic Analysis via Immunoblot 
The first step in the proteomic analysis was to probe for the presence of proteins that 
are known to be associated with VLDL. ApolipoproteinB100 is the main structural protein of 
VLDL (7, 33, 64). As shown in Figure 13, the PG-VTV concentrated both the 520 kDa apoB100 
isoform and the 250 kDa apoB48 forms, indicating the fact that these vesicles do indeed 
facilitate the transport of VLDL. As expected, the 46 kDa apolipoproteinAIV (apoAIV) was also 
detected in PG-VTVs, apoAIV serves in interacting with apoB enhancing the ability to expanding 
VLDL’s size thus facilitating the secretion of TAG (65). Interestingly as shown in figure 14, apoAI, 
which is not present on the VTV was present on the PG-VTV, signifying that it is transported to 
the Golgi apparatus by a mechanism separate from the lipoprotein vesicle. The v-SNARE VAMP7 
was detected on the PG-VTV which alludes to its potential role in being the tethering molecule 
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responsible for directing this vesicle to the plasma membrane. Syntaxin5, a t-SNARE was not 
detected on the PG-VTV. 
 
 
Figure 13 – PG-VTV Western Blot Analysis 
Western blot analysis of hepatic ER, Golgi, and PG-VTV. Samples (40 μg of protein) were 
resolved on a 4-20% gradient SDS-PAGE gel. 
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Figure 14 – ApolipoproteinAI added to PG-VTV 
Western blot analysis of hepatic ER, Golgi, PG-VTV, and VTV. Samples (40 μg of protein) were 
resolved on a 4-20% gradient SDS-PAGE gel and probed with anti apoAI antibody and its 
corresponding secondary antibody and developed on film. 
 
 
2D Comparative Proteomic Analysis 
A comparative proteomic analysis was undertaken to compare the PG-VTV proteome 
with the currently known VTV proteome. The method utilized was 2D-DIGE as it allows the 
simultaneous resolution between two samples in the same gel. The scans shown in figure 15 
show the VTV protein that was labeled with Cy3 a fluorescent dye that appears in green, and 
the PG-VTV protein that was labeled with Cy5, a fluorophore that appears in red.  
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Figure 15 – 2D-DIGE Comparative Analysis 
A 2D-DIGE analysis was performed on VTV and PG-VTV samples (50 μg of protein). VTV was 
labeled with Cy3 fluorescent dye (left), PG-VTV sample was labeled with Cy5 dye (center), and 
overlay was analyzed (right). 
 
 
As shown in figure 14, the proteomic profile of the PG-VTV was very similar to the VTV 
proteome in both shape and composition, however there were several spots that were unique 
to the post Golgi vesicle. As shown in the merge in figure 16, these spots have been highlighted. 
These spots are of interest for future study as they may be indicative to regulatory entities that 
are necessary for PG-VTV biogeneration and direction towards the plasma membrane. 
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Figure 16 – Analysis of 2D-DIGE Merge 
The overlay of the VTV & PG-VTV 2D-DIGE analysis was analyzed for differences. Circled spots 
are indicative of protein unique to the PG-VTV sample.  
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CHAPTER FIVE: CONCLUSION 
The data resulting from these studies were indicative of the fact that a unique, 
specialized vesicle is responsible for transporting mature VLDL from its site of maturation, 
which is the Golgi lumen, to the plasma membrane for its eventual secretion to the 
bloodstream. This step is required for the secretion of matured VLDL from the hepatocyte and 
thus studying its required steps are necessary to fully elucidate the hepatic lipoprotein 
secretory pathway. 
The overall secretion pathway, with regards to trafficking, is shown in Figure 2. The VLDL 
synthesis begins in the lumen of the ER. Upon initial assembly, this premature VLDL molecule is 
transported to the Golgi lumen for maturation. This first transport step is mediated by the VTV, 
a unique COPII-dependent vesicle. Upon docking and fusion with the cis-Golgi membranes VTV 
delivers VLDL Golgi lumen. It is here where the VLDL molecule undergoes several modifications 
as it traverses the cisternae of the Golgi including the incorporation of apoAI and apoE 
lipoproteins, and the phosphorylation and glycosylation of the apoB100 protein backbone. 
Upon maturation, this VLDL molecule is ready for secretion from the hepatocyte. In a complex 
process involving cargo selection, membrane deformation, and curvature, the matured VLDL 
molecule is incorporated in a vesicle, the PG-VTV.  
The PG-VTV facilitates VLDL exit from the trans-Golgi face and encloses it in a vesicle of 
300-320 nm in diameter, one that is large enough to facilitate a VLDL sized molecule (80-100 
nm). This vesicle’s morphology is one that confirms the fact that it is a vesicle shaped enclosed 
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intracellular compartment, which could enclose the VLDL and protect it from the cytosolic 
lipases and proteases. 
The vesicle is free of contamination from organelle marker proteins, and does not 
contain Sec22b, which is present on the VTV and functions as its v-SNARE. These indicate that 
the PG-VTV is a newly isolated vesicle unique to the VTV and not fragments of broken organelle 
membranes. 
The formation of this vesicle requires the physiological temperature of 37°C, the 
presence of energy in the form of ATP, and cytosolic protein. All these conditions that are 
established conditions for vesicular formation. If any of these conditions are altered, then the 
presence of [3H]TAG, our marker for VLDL, is severely abrogated in the light density fractions 
where we normally find the PG-VTV.  
The vesicle is functional in its ability to transfer VLDL, indicated by a transfer of dpm, to 
the plasma membrane. More importantly, this transport step is unidirectional as shown by data 
indicating the vesicle does not fuse with the Golgi membranes and cannot deliver VLDL to the 
Golgi lumen. The PG-VTV does indeed deliver VLDL to the plasma membrane successfully. 
Furthermore, the correct orientation of the plasma membrane is necessary, the PG-VTVs can 
only deliver their VLDL cargo if the cytosolic side of the plasma membrane is exposed for 
reaction. The fusion of PG-VTV with correctly oriented plasma membrane also requires the 
presence of cytosolic protein and the correct physiological temperature of 37°C. These 
requirements further indicate the function of these vesicles under physiological conditions and 
correlates with widely established requirements for vesicular fusion. 
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The vesicle’s proteomic profile is unique and contains lipoproteins necessary and known 
to exist in matured VLDL present in the bloodstream. The comparative 2D gel analysis 
undergone signifies that this vesicle furthermore is similar to the VTV, stating the fact that it is 
indeed a vesicle responsible for transporting VLDL, yet this vesicle transports matured VLDL and 
contains unique protein necessary for the post-Golgi transport step. 
Table 2 summarizes key points and differences between the PCTV or the vesicle 
responsible for transporting nascent chylomicrons in the intestine, the VTV, and the PG-VTV. 
 
Table 2 – Summary of Lipoprotein Transport Vesicles 
 PCTV VTV PG-VTV Reference 
Size 142-500nm 100-120nm 300-320nm (33, 66) 
v-SNARE VAMP7 Sec22b VAMP7 (33, 66-68) 
t-SNAREs Syntaxin5, rBet1, 
vti1a 
Syntaxin5, rBet1, 
GOS28 
Syntaxin1, SNAP23 
(Hypothesized) 
(33, 66-68) 
Coat COPII independent COPII dependent  (33, 68) 
GTP 
requirement 
No Yes Yes (33, 66) 
Initiator L-FABP Sar1  (33, 67) 
Direction ER to Golgi - intestine ER to Golgi - liver Golgi to PM - liver (33, 66) 
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In the study herein, the PG-VTV has been shown to be the unique specialized vesicle 
responsible for transport of mature VLDL from the Golgi apparatus to the plasma membrane for 
secretion. This vesicle is unique in proteome and morphology from currently known vesicles. 
Moreover, this vesicle requires physiological conditions for its biogenesis. The vesicle is 
functional in its ability to fuse with the plasma membrane and deliver its VLDL cargo for 
secretion. The proteomic profile of PG-VTV that has been conducted will provide a basic tool for 
studies with focus on lipoprotein and may prove to have vast implications for the future of 
cardiovascular research. 
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APPENDIX: IACUC ANIMAL PROTOCOL APPROVAL LETTER 
 
  
 43 
 
 44 
  
 45 
REFERENCES 
1. Mansbach, C. M., and Siddiqi, S. A. (2010) The biogenesis of chylomicrons, Annual 
review of physiology 72, 315-333. 
2. Stralfors, P. (1990) Autolysis of isolated adipocytes by endogenously produced fatty 
acids, FEBS letters 263, 153-154. 
3. Olofsson, S. O., and Boren, J. (2005) Apolipoprotein B: a clinically important 
apolipoprotein which assembles atherogenic lipoproteins and promotes the 
development of atherosclerosis, Journal of internal medicine 258, 395-410. 
4. Skalen, K., Gustafsson, M., Rydberg, E. K., Hulten, L. M., Wiklund, O., Innerarity, T. L., 
and Boren, J. (2002) Subendothelial retention of atherogenic lipoproteins in early 
atherosclerosis, Nature 417, 750-754. 
5. Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., 
Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., 
Heit, J. A., Howard, V. J., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., 
Lisabeth, L. D., Makuc, D. M., Marcus, G. M., Marelli, A., Matchar, D. B., Moy, C. S., 
Mozaffarian, D., Mussolino, M. E., Nichol, G., Paynter, N. P., Soliman, E. Z., Sorlie, P. D., 
Sotoodehnia, N., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D., and Turner, M. B. 
(2011) Heart Disease and Stroke Statistics—2012 Update, Circulation. 
6. Siddiqi, S. A., Siddiqi, S., Mahan, J., Peggs, K., Gorelick, F. S., and Mansbach, C. M., 2nd. 
(2006) The identification of a novel endoplasmic reticulum to Golgi SNARE complex used 
by the prechylomicron transport vesicle, The Journal of biological chemistry 281, 20974-
20982. 
7. Tiwari, S., and Siddiqi, S. A. (2012) Intracellular trafficking and secretion of VLDL, 
Arteriosclerosis, thrombosis, and vascular biology 32, 1079-1086. 
8. Pan, M., Liang Js, J. S., Fisher, E. A., and Ginsberg, H. N. (2002) The late addition of core 
lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of 
triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer 
protein activity and new triglyceride synthesis, The Journal of biological chemistry 277, 
4413-4421. 
9. Alexander, C. A., Hamilton, R. L., and Havel, R. J. (1976) Subcellular localization of B 
apoprotein of plasma lipoproteins in rat liver, The Journal of cell biology 69, 241-263. 
 46 
10. Ginsberg, H. N., and Fisher, E. A. (2009) The ever-expanding role of degradation in the 
regulation of apolipoprotein B metabolism, Journal of lipid research 50 Suppl, S162-166. 
11. Yamaguchi, J., Conlon, D. M., Liang, J. J., Fisher, E. A., and Ginsberg, H. N. (2006) 
Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet 
domains, not pause transfer sequences, The Journal of biological chemistry 281, 27063-
27071. 
12. Segrest, J. P., Jones, M. K., Mishra, V. K., Anantharamaiah, G. M., and Garber, D. W. 
(1994) apoB-100 has a pentapartite structure composed of three amphipathic alpha-
helical domains alternating with two amphipathic beta-strand domains. Detection by 
the computer program LOCATE, Arteriosclerosis and thrombosis : a journal of vascular 
biology / American Heart Association 14, 1674-1685. 
13. Cladaras, C., Hadzopoulou-Cladaras, M., Nolte, R. T., Atkinson, D., and Zannis, V. I. 
(1986) The complete sequence and structural analysis of human apolipoprotein B-100: 
relationship between apoB-100 and apoB-48 forms, The EMBO journal 5, 3495-3507. 
14. Davidson, N. O., and Shelness, G. S. (2000) APOLIPOPROTEIN B: mRNA editing, 
lipoprotein assembly, and presecretory degradation, Annual review of nutrition 20, 169-
193. 
15. Tennyson, G. E., Sabatos, C. A., Higuchi, K., Meglin, N., and Brewer, H. B., Jr. (1989) 
Expression of apolipoprotein B mRNAs encoding higher- and lower-molecular weight 
isoproteins in rat liver and intestine, Proceedings of the National Academy of Sciences of 
the United States of America 86, 500-504. 
16. Chuck, S. L., and Lingappa, V. R. (1992) Pause transfer: a topogenic sequence in 
apolipoprotein B mediates stopping and restarting of translocation, Cell 68, 9-21. 
17. Liang, J., Wu, X., Jiang, H., Zhou, M., Yang, H., Angkeow, P., Huang, L. S., Sturley, S. L., 
and Ginsberg, H. (1998) Translocation efficiency, susceptibility to proteasomal 
degradation, and lipid responsiveness of apolipoprotein B are determined by the 
presence of beta sheet domains, The Journal of biological chemistry 273, 35216-35221. 
18. Fisher, E. A. (2012) The degradation of apolipoprotein B100: multiple opportunities to 
regulate VLDL triglyceride production by different proteolytic pathways, Biochimica et 
biophysica acta 1821, 778-781. 
19. Benoist, F., and Grand-Perret, T. (1997) Co-translational degradation of apolipoprotein 
B100 by the proteasome is prevented by microsomal triglyceride transfer protein. 
Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal 
triglyceride transfer protein, The Journal of biological chemistry 272, 20435-20442. 
 47 
20. Yeung, S. J., Chen, S. H., and Chan, L. (1996) Ubiquitin-proteasome pathway mediates 
intracellular degradation of apolipoprotein B, Biochemistry 35, 13843-13848. 
21. Fisher, E. A., Zhou, M., Mitchell, D. M., Wu, X., Omura, S., Wang, H., Goldberg, A. L., and 
Ginsberg, H. N. (1997) The degradation of apolipoprotein B100 is mediated by the 
ubiquitin-proteasome pathway and involves heat shock protein 70, The Journal of 
biological chemistry 272, 20427-20434. 
22. Gusarova, V., Caplan, A. J., Brodsky, J. L., and Fisher, E. A. (2001) Apoprotein B 
degradation is promoted by the molecular chaperones hsp90 and hsp70, The Journal of 
biological chemistry 276, 24891-24900. 
23. Oyadomari, S., Yun, C., Fisher, E. A., Kreglinger, N., Kreibich, G., Oyadomari, M., Harding, 
H. P., Goodman, A. G., Harant, H., Garrison, J. L., Taunton, J., Katze, M. G., and Ron, D. 
(2006) Cotranslocational degradation protects the stressed endoplasmic reticulum from 
protein overload, Cell 126, 727-739. 
24. Hrizo, S. L., Gusarova, V., Habiel, D. M., Goeckeler, J. L., Fisher, E. A., and Brodsky, J. L. 
(2007) The Hsp110 molecular chaperone stabilizes apolipoprotein B from endoplasmic 
reticulum-associated degradation (ERAD), The Journal of biological chemistry 282, 
32665-32675. 
25. Fisher, E. A., and Williams, K. J. (2008) Autophagy of an oxidized, aggregated protein 
beyond the ER: a pathway for remarkably late-stage quality control, Autophagy 4, 721-
723. 
26. Rutledge, A. C., Qiu, W., Zhang, R., Kohen-Avramoglu, R., Nemat-Gorgani, N., and Adeli, 
K. (2009) Mechanisms targeting apolipoprotein B100 to proteasomal degradation: 
evidence that degradation is initiated by BiP binding at the N terminus and the 
formation of a p97 complex at the C terminus, Arteriosclerosis, thrombosis, and vascular 
biology 29, 579-585. 
27. Swift, L. L. (1995) Assembly of very low density lipoproteins in rat liver: a study of 
nascent particles recovered from the rough endoplasmic reticulum, Journal of lipid 
research 36, 395-406. 
28. Hussain, M. M., Shi, J., and Dreizen, P. (2003) Microsomal triglyceride transfer protein 
and its role in apoB-lipoprotein assembly, Journal of lipid research 44, 22-32. 
29. Shoulders, C. C., and Shelness, G. S. (2005) Current biology of MTP: implications for 
selective inhibition, Current topics in medicinal chemistry 5, 283-300. 
 48 
30. Rustaeus, S., Lindberg, K., Stillemark, P., Claesson, C., Asp, L., Larsson, T., Boren, J., and 
Olofsson, S. O. (1999) Assembly of very low density lipoprotein: a two-step process of 
apolipoprotein B core lipidation, The Journal of nutrition 129, 463S-466S. 
31. Higgins, J. A. (1988) Evidence that during very low density lipoprotein assembly in rat 
hepatocytes most of the triacylglycerol and phospholipid are packaged with 
apolipoprotein B in the Golgi complex, FEBS Lett 232, 405-408. 
32. Bamberger, M. J., and Lane, M. D. (1990) Possible role of the Golgi apparatus in the 
assembly of very low density lipoprotein, Proceedings of the National Academy of 
Sciences of the United States of America 87, 2390-2394. 
33. Siddiqi, S. A. (2008) VLDL exits from the endoplasmic reticulum in a specialized vesicle, 
the VLDL transport vesicle, in rat primary hepatocytes, The Biochemical journal 413, 
333-342. 
34. Rahim, A., Nafi-valencia, E., Siddiqi, S., Basha, R., Runyon, C. C., and Siddiqi, S. A. (2012) 
Proteomic analysis of the very low density lipoprotein (VLDL) transport vesicles, Journal 
of proteomics 75, 2225-2235. 
35. Barlowe, C. (1998) COPII and selective export from the endoplasmic reticulum, 
Biochimica et biophysica acta 1404, 67-76. 
36. Hughes, H., and Stephens, D. J. (2008) Assembly, organization, and function of the COPII 
coat, Histochemistry and cell biology 129, 129-151. 
37. Gurkan, C., Stagg, S. M., Lapointe, P., and Balch, W. E. (2006) The COPII cage: unifying 
principles of vesicle coat assembly, Nature reviews. Molecular cell biology 7, 727-738. 
38. Jensen, D., and Schekman, R. (2011) COPII-mediated vesicle formation at a glance, 
Journal of cell science 124, 1-4. 
39. Matsuoka, K., Orci, L., Amherdt, M., Bednarek, S. Y., Hamamoto, S., Schekman, R., and 
Yeung, T. (1998) COPII-coated vesicle formation reconstituted with purified coat 
proteins and chemically defined liposomes, Cell 93, 263-275. 
40. Shoulders, C. C., Stephens, D. J., and Jones, B. (2004) The intracellular transport of 
chylomicrons requires the small GTPase, Sar1b, Current opinion in lipidology 15, 191-
197. 
41. Kuge, O., Dascher, C., Orci, L., Rowe, T., Amherdt, M., Plutner, H., Ravazzola, M., 
Tanigawa, G., Rothman, J. E., and Balch, W. E. (1994) Sar1 promotes vesicle budding 
 49 
from the endoplasmic reticulum but not Golgi compartments, The Journal of cell biology 
125, 51-65. 
42. Gusarova, V., Brodsky, J. L., and Fisher, E. A. (2003) Apolipoprotein B100 exit from the 
endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density 
lipoprotein occurs post-ER, The Journal of biological chemistry 278, 48051-48058. 
43. Tiwari, S., Siddiqi, S., and Siddiqi, S. A. (2013) CideB protein is required for the biogenesis 
of very low density lipoprotein (VLDL) transport vesicle, The Journal of biological 
chemistry 288, 5157-5165. 
44. Sudhof, T. C., and Rothman, J. E. (2009) Membrane fusion: grappling with SNARE and SM 
proteins, Science 323, 474-477. 
45. Hay, J. C., and Scheller, R. H. (1997) SNAREs and NSF in targeted membrane fusion, 
Current opinion in cell biology 9, 505-512. 
46. Siddiqi, S., Mani, A. M., and Siddiqi, S. A. (2010) The identification of the SNARE complex 
required for the fusion of VLDL-transport vesicle with hepatic cis-Golgi, The Biochemical 
journal 429, 391-401. 
47. Tran, K., Thorne-Tjomsland, G., DeLong, C. J., Cui, Z., Shan, J., Burton, L., Jamieson, J. C., 
and Yao, Z. (2002) Intracellular assembly of very low density lipoproteins containing 
apolipoprotein B100 in rat hepatoma McA-RH7777 cells, The Journal of biological 
chemistry 277, 31187-31200. 
48. Macri, J., and Adeli, K. (1997) Conformational changes in apolipoprotein B modulate 
intracellular assembly and degradation of ApoB-containing lipoprotein particles in 
HepG2 cells, Arteriosclerosis, thrombosis, and vascular biology 17, 2982-2994. 
49. Gusarova, V., Seo, J., Sullivan, M. L., Watkins, S. C., Brodsky, J. L., and Fisher, E. A. (2007) 
Golgi-associated maturation of very low density lipoproteins involves conformational 
changes in apolipoprotein B, but is not dependent on apolipoprotein E, The Journal of 
biological chemistry 282, 19453-19462. 
50. Ginsberg, H. N. (1995) Synthesis and secretion of apolipoprotein B from cultured liver 
cells, Current opinion in lipidology 6, 275-280. 
51. Bonifacino, J. S., and Glick, B. S. (2004) The mechanisms of vesicle budding and fusion, 
Cell 116, 153-166. 
52. Muth, T. R., and Caplan, M. J. (2003) Transport protein trafficking in polarized cells, 
Annual review of cell and developmental biology 19, 333-366. 
 50 
53. Rodriguez-Boulan, E., Kreitzer, G., and Musch, A. (2005) Organization of vesicular 
trafficking in epithelia, Nature reviews. Molecular cell biology 6, 233-247. 
54. Rodriguez-Boulan, E., and Musch, A. (2005) Protein sorting in the Golgi complex: shifting 
paradigms, Biochimica et biophysica acta 1744, 455-464. 
55. Graham, T. R., and Burd, C. G. (2011) Coordination of Golgi functions by 
phosphatidylinositol 4-kinases, Trends in cell biology 21, 113-121. 
56. Wang, Y. J., Wang, J., Sun, H. Q., Martinez, M., Sun, Y. X., Macia, E., Kirchhausen, T., 
Albanesi, J. P., Roth, M. G., and Yin, H. L. (2003) Phosphatidylinositol 4 phosphate 
regulates targeting of clathrin adaptor AP-1 complexes to the Golgi, Cell 114, 299-310. 
57. De Matteis, M., Godi, A., and Corda, D. (2002) Phosphoinositides and the golgi complex, 
Current opinion in cell biology 14, 434-447. 
58. Munro, S. (2003) Lipid rafts: elusive or illusive?, Cell 115, 377-388. 
59. Bard, F., and Malhotra, V. (2006) The formation of TGN-to-plasma-membrane transport 
carriers, Annual review of cell and developmental biology 22, 439-455. 
60. Liljedahl, M., Maeda, Y., Colanzi, A., Ayala, I., Van Lint, J., and Malhotra, V. (2001) 
Protein kinase D regulates the fission of cell surface destined transport carriers from the 
trans-Golgi network, Cell 104, 409-420. 
61. Baron, C. L., and Malhotra, V. (2002) Role of diacylglycerol in PKD recruitment to the 
TGN and protein transport to the plasma membrane, Science 295, 325-328. 
62. Hughson, F. M. (2010) Copy coats: COPI mimics clathrin and COPII, Cell 142, 19-21. 
63. Shiba, Y., Romer, W., Mardones, G. A., Burgos, P. V., Lamaze, C., and Johannes, L. (2010) 
AGAP2 regulates retrograde transport between early endosomes and the TGN, Journal 
of cell science 123, 2381-2390. 
64. Brodsky, J. L., and Fisher, E. A. (2008) The many intersecting pathways underlying 
apolipoprotein B secretion and degradation, Trends in endocrinology and metabolism: 
TEM 19, 254-259. 
65. Weinberg, R. B., Gallagher, J. W., Fabritius, M. A., and Shelness, G. S. (2012) ApoA-IV 
modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins, 
Journal of lipid research 53, 736-743. 
66. Siddiqi, S., Saleem, U., Abumrad, N. A., Davidson, N. O., Storch, J., Siddiqi, S. A., and 
Mansbach, C. M., 2nd. (2010) A novel multiprotein complex is required to generate the 
 51 
prechylomicron transport vesicle from intestinal ER, Journal of lipid research 51, 1918-
1928. 
67. Neeli, I., Siddiqi, S. A., Siddiqi, S., Mahan, J., Lagakos, W. S., Binas, B., Gheyi, T., Storch, J., 
and Mansbach, C. M., 2nd. (2007) Liver fatty acid-binding protein initiates budding of 
pre-chylomicron transport vesicles from intestinal endoplasmic reticulum, The Journal of 
biological chemistry 282, 17974-17984. 
68. Siddiqi, S. A., Gorelick, F. S., Mahan, J. T., and Mansbach, C. M., 2nd. (2003) COPII 
proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the 
pre-chylomicron transport vesicle, Journal of cell science 116, 415-427. 
 
 
